Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer

Sorafenib, the first agent developed to target BRAF mutant melanoma, is a multi-kinase inhibitor that was approved by the FDA for therapy of kidney and subsequently liver cancer, and is currently in clinical trials for thyroid, lung and brain cancer. Colorectal cancer with V600E BRAF mutation has sh...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Al-Marrawi, Mhd Yaser, Saroya, Bikramajit Singh, Brennan, Matthew C, Yang, Zhaohai, Dykes, Thomas M, El-Deiry, Wafik S
Формат: Artigo
Язык:Inglês
Опубликовано: Landes Bioscience 2013
Предметы:
Bedside to Bench Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3841209/
https://ncbi.nlm.nih.gov/pubmed/23792568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.25191
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы